ADC Therapeutics SA (ADCT) Reports Q2 Loss, Tops Revenue Estimates

Core Insights - ADC Therapeutics reported a quarterly loss of $0.5 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.36, marking an earnings surprise of -38.89% [1] - The company generated revenues of $18.84 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 0.58% and showing an increase from $17.41 million year-over-year [2] - The stock has increased by approximately 34.7% since the beginning of the year, outperforming the S&P 500's gain of 8.4% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.37 on revenues of $19.13 million, while for the current fiscal year, it is -$1.58 on revenues of $77.93 million [7] - The estimate revisions trend for ADC Therapeutics was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which ADC Therapeutics belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, suggesting potential challenges for stock performance [8] - Another company in the same industry, Alvotech, is expected to report a quarterly loss of $0.26 per share, reflecting a significant year-over-year decline of -192.9% [9]